Trials / Unknown
UnknownNCT04407858
Cardiovascular Complications of Carfilzomib
Insuffisance Cardiaque Sous Carfilzomib: étude Prospective
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- European Georges Pompidou Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
Conditions
Timeline
- Start date
- 2020-05-21
- Primary completion
- 2021-05-21
- Completion
- 2022-05-21
- First posted
- 2020-05-29
- Last updated
- 2020-06-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04407858. Inclusion in this directory is not an endorsement.